期刊
NATURE COMMUNICATIONS
卷 7, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms11544
关键词
-
资金
- National Institutes of Health under the B cell Epitope Discovery and Mechanisms of Antibody Protection programme [HSN272200900049C, BAA-NIAID-DAIT-NIHAI2008031]
- NIH [AI067188, AI067927, AI070530, AI081982, AI082119, AI082805, AI088843, AI104216, AI104621, AI115754, P20GM103501, 1U01HG007480-01]
- World Bank
- Bill and Melinda Gates Foundation
- Paul G. Allen Family Foundation
- Sierra Leonean Ministry of Health and Sanitation
- Nigerian Ministry of Health
Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据